Listen Now
Topics Covered
- Novel Therapy for Adjuvant Hormone Receptor Positive Breast Cancer
- Antibody Drug Conjugates in First Line Metastatic Hormone Receptor Positive Breast Cancer
- Tailoring First Line Therapy in Metastatic HER2 Positive Breast Cancer
- Integration & Sequencing of Novel Oral Selective Estrogen Receptor Degraders (SERDs) in Metastatic Hormone Receptor Positive Breast Cancer
- Deescalating Therapy in Low-Risk Ductal Carcinoma In Situ (DCIS)
- Questions for Our Panel of Experts
Our Panel of Experts

Kate Lathrop, MD
Associate Professor, Division of Hematology and Oncology, UT Health San Antonio, Breast Medical Oncology, Mays Cancer Center at UT Health San Antonio, Assistant Dean of Undergraduate Research, Long School of Medicine, UT Health San Antonio, Program Director, Medical Oncology and Hematology Fellowship Program, UT Health San Antonio, Program Director, San Antonio Breast Cancer Symposium (SABCS)

Kamel Abou Hussein, MD
Assistant Professor of Medicine, Cooper Medical School of Rowan University, Adjunct Assistant Professor, Department of Breast Medical Oncology, MD Anderson Cancer Center, Co-Director of the Janet Knowles Breast Cancer Program, Director of Breast Cancer Clinical Trials, MD Anderson Cancer Center at Cooper
Carolyn Messner, DSW, BCD, FAPOS, FAOSW
Senior Director of Education and Training, CancerCare
Brochure
You can download the brochure for this workshop
Workshop Date
This workshop was originally recorded on December 17, 2025.
